The SynGAP Research Fund 501(c)(3) dba Cure SYNGAP1 announced a $108,867 grant to Dr. Michael Courtney and Dr. Li-Li Li at the Turku Bioscience Centre, University of Turku, Finland, to advance their research on SYNGAP1 missense variants. Their project seeks to better understand the functional impact of these mutations and explore drug repurposing as a potential therapeutic approach.

Dr. Courtney’s team will use advanced phenotyping techniques to assess how SYNGAP1 missense variants impact the protein’s interaction with key neuronal components, such as PSD95, which is crucial for synaptic function. The project will also evaluate repurposed drugs like Nortriptyline and Tanganil for their ability to restore normal protein function. This comprehensive approach could lead to new therapeutic strategies for patients with SYNGAP1-Related Disorders (SRD). >> Keep reading